Montefiore Health System and Albert Einstein College of Medicine jointly announced on Tuesday the launch of the Adaptive COVID-19 Treatment Trial (ACTT 2) to evaluate treatment options of baricitinib and remdesivir for people hospitalized with severe COVID-19 infection, under a sponsorship agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The preliminary results from the antiviral drug remdesivir in a multicenter trial showed that patients with COVID-19 who received remdesivir recovered in 11 days on average, over 15 days for patients in the placebo group. Remdesivir was developed by Gilead Sciences Inc.
This trial is now studying remdesivir in combination with inflammatory drug baricitinib or placebo in a double-blind, randomized trial in people with COVID-19 to prevent or reduce the hyper-inflammatory effect that can fatally overwhelm the lungs and other parts of the body when their immune system reacts to coronavirus infection. Baricitinib was developed by Eli Lilly and Company.
Under the ACTT 2 trial, all patients will receive remdesivir intravenously for up to ten days. Half of the patients will be given baricitinib by mouth, with the remaining half receiving an identical placebo, both for up to 14 days, concluded the companies.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary